Rheumatoid Arthritis - Heat Map and Analysis Research Report
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders the mobility of the patient and can have a substantial impact on quality of life.
12207(firmenpresse) - Albany, New York, January 16, 2017: The latest report focusing on the Pharmaceutical Market has been recently added to the online database of Market Research Hub’s repository. The report covers the present scenario and the growth prospects of the Health Market. It is entitled as “Rheumatoid Arthritis - Heat Map and Analysis”.
Request for Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=915791
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders the mobility of the patient and can have a substantial impact on quality of life. Therapeutic options for the treatment of RA have grown rapidly over the past two decades, having also expanded to encompass a number of highly successful biologics. Although clinically and commercially successful, there are a number of unmet needs in this market.
The differences between many of these products are relatively nuanced, and must be understood fully by companies seeking to position a novel drug in this market. This tabular heat map framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed readouts of all late-stage clinical trial results for products in the RA market and Phase III pipeline. These are split along lines of therapy, and so are reflective of the treatment algorithm used in the clinic.
All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population, are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease-of-use.
Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=915791
The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.
Scope
The rheumatoid arthritis market landscape is expected to change substantially with the advent of promising novel pipeline products.
What are the clinical characteristics of currently approved therapies for rheumatoid arthritis, in terms of specific safety and efficacy parameters?
What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?
How will current late-stage IL-6 inhibitors affect the market for biologic DMARDs, and are they able to yield comparable clinical efficacy results to TNF-a therapies?
With four targeted synthetic DMARDs present in the late-stage pipeline, do they have sufficient differentiating characteristics to make a strong impact on the market?
How will the influx of biosimilar TNF-a inhibitors affect the competitive landscape?
Browse Full Info with TOC: http://www.marketresearchhub.com/report/rheumatoid-arthritis-heat-map-and-analysis-report.html
Reasons to buy
Understand the current clinical landscape by considering the treatment options available for each patient segment.
Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy
Understand the relative strengths and weaknesses of the studies used to gather these data.
Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks
Assess one?s own pipeline program in light of these benchmarks in order to optimally position this program and maximize uptake by clinicians
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press(at)marketresearchhub.com
Website: http://www.marketresearchhub.com/
Datum: 16.01.2017 - 08:15 Uhr
Sprache: Deutsch
News-ID 517655
Anzahl Zeichen: 4542
contact information:
Contact person: Mark Hub
Town:
Albany
Phone: 5186212074
Kategorie:
Healthcare & Medical
Typ of Press Release: bitte
type of sending: Veröffentlichung
Date of sending: 16.01.2017
Diese Pressemitteilung wurde bisher 385 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Rheumatoid Arthritis - Heat Map and Analysis Research Report"
steht unter der journalistisch-redaktionellen Verantwortung von
Market Research HUB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
